Chugai Pharmaceutical Co., Ltd.

TSE:4519 Stock Report

Market Cap: JP¥10.3t

Chugai Pharmaceutical Management

Management criteria checks 1/4

Chugai Pharmaceutical's CEO is Osamu Okuda, appointed in Mar 2020, has a tenure of 4.33 years. total yearly compensation is ¥375.00M, comprised of 31.7% salary and 68.3% bonuses, including company stock and options. directly owns 0.01% of the company’s shares, worth ¥989.49M. The average tenure of the management team and the board of directors is 3.8 years and 1.3 years respectively.

Key information

Osamu Okuda

Chief executive officer

JP¥375.0m

Total compensation

CEO salary percentage31.7%
CEO tenure4.3yrs
CEO ownership0.01%
Management average tenure3.8yrs
Board average tenure1.3yrs

Recent management updates

Recent updates

Chugai Pharmaceutical (TSE:4519) Is Due To Pay A Dividend Of ¥41.00

Jul 27
Chugai Pharmaceutical (TSE:4519) Is Due To Pay A Dividend Of ¥41.00

Estimating The Intrinsic Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)

Jul 15
Estimating The Intrinsic Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)

Chugai Pharmaceutical (TSE:4519) Is Increasing Its Dividend To ¥41.00

Jun 19
Chugai Pharmaceutical (TSE:4519) Is Increasing Its Dividend To ¥41.00

Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Business Is Trailing The Market But Its Shares Aren't

Jun 17
Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Business Is Trailing The Market But Its Shares Aren't

Chugai Pharmaceutical (TSE:4519) Is Paying Out A Larger Dividend Than Last Year

May 04
Chugai Pharmaceutical (TSE:4519) Is Paying Out A Larger Dividend Than Last Year

We Think That There Are Some Issues For Chugai Pharmaceutical (TSE:4519) Beyond Its Promising Earnings

May 01
We Think That There Are Some Issues For Chugai Pharmaceutical (TSE:4519) Beyond Its Promising Earnings

Chugai Pharmaceutical Co., Ltd. (TSE:4519) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Apr 26
Chugai Pharmaceutical Co., Ltd. (TSE:4519) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Chugai Pharmaceutical Co., Ltd. (TSE:4519) Investors Are Less Pessimistic Than Expected

Mar 01
Chugai Pharmaceutical Co., Ltd. (TSE:4519) Investors Are Less Pessimistic Than Expected

CEO Compensation Analysis

How has Osamu Okuda's remuneration changed compared to Chugai Pharmaceutical's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

JP¥355b

Mar 31 2024n/an/a

JP¥326b

Dec 31 2023JP¥375mJP¥119m

JP¥325b

Sep 30 2023n/an/a

JP¥337b

Jun 30 2023n/an/a

JP¥327b

Mar 31 2023n/an/a

JP¥316b

Dec 31 2022JP¥298mJP¥108m

JP¥374b

Sep 30 2022n/an/a

JP¥371b

Jun 30 2022n/an/a

JP¥389b

Mar 31 2022n/an/a

JP¥387b

Dec 31 2021JP¥252mJP¥85m

JP¥303b

Sep 30 2021n/an/a

JP¥256b

Jun 30 2021n/an/a

JP¥231b

Mar 31 2021n/an/a

JP¥211b

Dec 31 2020JP¥84mJP¥40m

JP¥215b

Compensation vs Market: Osamu's total compensation ($USD2.44M) is above average for companies of similar size in the JP market ($USD1.60M).

Compensation vs Earnings: Osamu's compensation has increased by more than 20% in the past year.


CEO

Osamu Okuda (61 yo)

4.3yrs

Tenure

JP¥375,000,000

Compensation

Dr. Osamu Okuda serves as Representative Director and President at Chugai Pharmaceutical Co., Ltd. since March 30, 2020 and its Chief Executive Officer since March 23, 2021. He serves as Chairman at Chugai...


Leadership Team

NamePositionTenureCompensationOwnership
Osamu Okuda
President4.3yrsJP¥375.00m0.0096%
¥ 989.5m
Iwaaki Taniguchi
Executive VPless than a yearno data0.00012%
¥ 12.4m
Toshiya Sasai
Executive of Investor Relations Group & Corporate Communications Departmentno datano datano data
Masayoshi Higuchi
VP and Head of Qualityless than a yearno datano data
Junichi Takano
Head of Marketing & Sales Divisionno datano datano data
Shinji Hidaka
Executive Vice Presidentless than a yearno datano data
Junichi Ebihara
Executive Vice President3.5yrsno datano data
Yoshiaki Ohashi
Senior VP & Full-time Audit Supervisory Board Member9.5yrsno data0.0030%
¥ 307.2m
Tetsuya Yamaguchi
Executive VP & Head of PHC Solution Unit4.5yrsno datano data
Yoshiyuki Yano
Executive Vice Presidentno datano datano data
Tomoyuki Igawa
VP & Head of Research Divisionno datano datano data
Kaori Ouchi
Executive Vice President4yrsno datano data

3.8yrs

Average Tenure

61yo

Average Age

Experienced Management: 4519's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Osamu Okuda
President4.3yrsJP¥375.00m0.0096%
¥ 989.5m
Iwaaki Taniguchi
Executive VPless than a yearno data0.00012%
¥ 12.4m
Yoshiaki Ohashi
Senior VP & Full-time Audit Supervisory Board Member3.3yrsno data0.0030%
¥ 307.2m
Hitoshi Iikura
Executive VPless than a yearno datano data
Arnold Levine
Member of the International Advisory Councilno datano datano data
Osamu Nagayama
Honorary Chairman & Senior Advisor4.3yrsJP¥211.00mno data
Franz Humer
Member of the International Advisory Councilno datano datano data
Victor Halberstadt
Member of the International Advisory Councilno datano datano data
William A. Burns
Member of the International Advisory Councilno datano datano data
Henry Nordhoff
Chairman of the International Advisory Councilno datano datano data
Fumio Tateishi
Outside Independent Director1.3yrsno datano data
Teresa A. Graham
Non-Executive Director1.3yrsno datano data

1.3yrs

Average Tenure

75yo

Average Age

Experienced Board: 4519's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.